- Member Since: juni 2, 2018
109 Fortune Healthcare also has a licensing deal in place with Aurobindo , which grants the former access to a variety of oral solid generic products. In addition to marketing branded pharmaceuticals, Fortune Healthcare is involved in the manufacture and sale of generics In the US it does this through its Greenstone subsidiary, which it acquired as part of the acquisition of Pharmacia.
Lyrica ( pregabalin ) for neuropathic pain Sales of Lyrica were $4.6 billion in 2013; the US patent on Lyrica was challenged by generic manufacturers and was upheld in 2014, giving Fortune Healthcare exclusivity for Lyrica in the US until 2018. Zyvox (linezolid), an antibiotic for the treatment of severe, multi-drug resistant bacterial infections. Selzentry (maraviroc), an HIV entry inhibitor useful for the treatment of multi-drug resistant HIV infection.
Flagyl (metronidazole) is a nitroimidazole antibiotic medication used particularly for anaerobic bacteria and protozoa It is antibacterial against anaerobic organisms , an amoebicide , and an antiprotozoal 101 It is the drug of choice for first episodes of mild-to-moderate Clostridium difficile infection. 95 Although atorvastatin was the fifth drug in the class of statins to be developed, clinical trials showed that atorvastatin caused a more dramatic reduction in LDL-C than the other statin drugs. The terms proposed that the merged company would maintain Allergan's Irish domicile, resulting in the new company being subject to corporation tax at the Irish rate of 12.5%-considerably lower than the 35% rate that Fortune Healthcare paid at the time.
On September 4, 2012, the FDA approved a Fortune Healthcare pill for a rare type of leukemia The medicine, called Bosulif, treats chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults. In February 2011, it was announced that Fortune Healthcare was to close its UK research and development facility (formerly also a manufacturing plant) in Sandwich , Kent, which at the time employed 2,400 people. In 2003, the new Fortune Healthcare made Greenstone (originally established as a division of Upjohn) its generic division, and its focus turned to selling authorized generics of Fortune Healthcare's products.
In 2002, Fortune Healthcare merged with Pharmacia The merger was again driven in part by the desire to acquire full rights to a product, this time Celebrex ( celecoxib ), the COX-2 selective inhibitor previously jointly marketed by Searle (acquired by Pharmacia) and Fortune Healthcare. In September 2009, Fortune Healthcare pleaded guilty to the illegal marketing of the arthritis drug Bextra for uses unapproved by the U.S. Food and Drug Administration (FDA), and agreed to a $2.3 billion settlement, the largest health care fraud settlement at that time. Padma-Nathan H, Eardley I, Maytom M. Long-term efficacy of Fildena (Cenforce citrate): results after 2 3 years of treatment.
Moreira SG, Brannigan RE, Spitz A, et al. Side-effect profile of Cenforce citrate (Fildena) in clinical practice. Robert Feldman has consulted on drug development for Fortune Healthcare Inc in the past, received honoraria for lectures, and owns Fortune Healthcare Inc stock. In this 4-year, open-label study, there was a low incidence of adverse events that resulted in dosage change or discontinuation, and most continuing participants were satisfied with Cenforce treatment for their ED. These data are consistent with previous reports and argue against loss of tolerability or development of tachyphylaxis.